BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 32881999)

  • 1. Primary HPV and Molecular Cervical Cancer Screening in US Women Living With Human Immunodeficiency Virus.
    Strickler HD; Keller MJ; Hessol NA; Eltoum IE; Einstein MH; Castle PE; Massad LS; Flowers L; Rahangdale L; Atrio JM; Ramirez C; Minkoff H; Adimora AA; Ofotokun I; Colie C; Huchko MJ; Fischl M; Wright R; D'Souza G; Leider J; Diaz O; Sanchez-Keeland L; Shrestha S; Xie X; Xue X; Anastos K; Palefsky JM; Burk RD
    Clin Infect Dis; 2021 May; 72(9):1529-1537. PubMed ID: 32881999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P16/Ki-67 Dual Staining in Positive Human Papillomavirus DNA Testing for Predictive Diagnosis of Abnormal Cervical Lesions in Northeastern Thai Women.
    Aromseree S; Wongjumpa W; Ekalaksananan T; Temtanakitpaisan A; Kleebkaow P; Srisathaporn S; Tongchai P; Pientong C
    Asian Pac J Cancer Prev; 2022 Oct; 23(10):3405-3411. PubMed ID: 36308365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of HPV-16 and HPV-18 Genotyping and Cytological Testing as Triage Testing Within Human Papillomavirus-Based Screening in Mexico.
    Torres-Ibarra L; Cuzick J; Lorincz AT; Spiegelman D; Lazcano-Ponce E; Franco EL; Moscicki AB; Mahmud SM; Wheeler CM; Rivera-Paredez B; Hernández-López R; León-Maldonado L; Salmerón J;
    JAMA Netw Open; 2019 Nov; 2(11):e1915781. PubMed ID: 31747033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cervical Precancer Risk in HIV-Infected Women Who Test Positive for Oncogenic Human Papillomavirus Despite a Normal Pap Test.
    Keller MJ; Burk RD; Massad LS; Eltoum IE; Hessol NA; Castle PE; Anastos K; Xie X; Minkoff H; Xue X; D'Souza G; Flowers L; Levine AM; Colie C; Rahangdale L; Fischl MA; Palefsky JM; Strickler HD
    Clin Infect Dis; 2015 Nov; 61(10):1573-81. PubMed ID: 26187020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 7. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of partial HPV16/18 genotyping in stratifying HPV-positive women attending routine cervical cancer screening: a population-based cohort study.
    Gori S; Battagello J; Gustinucci D; Campari C; Zorzi M; Frayle H; Passamonti B; Sartori G; Bulletti S; Fodero C; Cesarini E; Faggiano R; Del Mistro A
    BJOG; 2021 Jul; 128(8):1353-1362. PubMed ID: 33326680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of HPV Genotyping Combined with p16/Ki-67 in Detection of Cervical Precancer and Cancer Among HPV-Positive Chinese Women.
    Jiang MY; Wu Z; Li T; Yu L; Zhang SK; Zhang X; Qu P; Sun P; Xi MR; Liu X; Liao G; Sun L; Zhang Y; Chen W; Qiao YL
    Cancer Prev Res (Phila); 2020 Feb; 13(2):163-172. PubMed ID: 31871224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial.
    Wright TC; Behrens CM; Ranger-Moore J; Rehm S; Sharma A; Stoler MH; Ridder R
    Gynecol Oncol; 2017 Jan; 144(1):51-56. PubMed ID: 28094038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Performance of human papillomavirus typing test in cervical precancer lesions and cervical cancer screening].
    Zhang SK; Luo XP; Li ZF; Su Z; Xia JC; Hu GY; Zhu YJ; Xie LX; Feng XX; Sun XB; Chen W; Qiao YL
    Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):252-256. PubMed ID: 32252206
    [No Abstract]   [Full Text] [Related]  

  • 12. A comparison of high-grade cervical abnormality risks in women living with and without human immunodeficiency virus undergoing routine cervical-cancer screening.
    Castle PE; Befano B; Schiffman M; Wentzensen N; Lorey T; Poitras N; Hyer M; Cheung LC
    Prev Med; 2022 Sep; 162():107157. PubMed ID: 35810936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triaging HPV-positive, cytology-negative cervical cancer screening results with extended HPV genotyping and p16
    Song F; Yan P; Huang X; Wang C; Qu X; Du H; Wu R
    BMC Infect Dis; 2021 Apr; 21(1):400. PubMed ID: 33931022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women.
    Aoyama-Kikawa S; Fujita H; Hanley SJB; Kasamo M; Kikuchi K; Torigoe T; Matsuno Y; Tamakoshi A; Sasaki T; Matsuura M; Kato Y; Dong P; Watari H; Saito T; Sengoku K; Sakuragi N
    Cancer Sci; 2018 Jun; 109(6):2003-2012. PubMed ID: 29660849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
    Wentzensen N; Schwartz L; Zuna RE; Smith K; Mathews C; Gold MA; Allen RA; Zhang R; Dunn ST; Walker JL; Schiffman M
    Clin Cancer Res; 2012 Aug; 18(15):4154-62. PubMed ID: 22675168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection Rate of High-Grade Cervical Neoplasia and Cost-Effectiveness of High-Risk Human Papillomavirus Genotyping with Reflex Liquid-based Cytology in Cervical Cancer Screening.
    Tay SK; Lin LE; Goh RC
    Ann Acad Med Singap; 2017 Jul; 46(7):267-273. PubMed ID: 28821890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk stratification of HPV-positive results using extended genotyping and cytology: Data from the baseline phase of the Onclarity trial.
    Stoler MH; Parvu V; Yanson K; Andrews J; Vaughan L
    Gynecol Oncol; 2023 Jul; 174():68-75. PubMed ID: 37149907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cervical precancer with human papillomavirus types other than 16 among HIV co-infected women.
    Massad LS; Xie X; Burk RD; D'Souza G; Darragh TM; Minkoff H; Colie C; Burian P; Palefsky J; Atrio J; Strickler HD
    Am J Obstet Gynecol; 2016 Mar; 214(3):354.e1-6. PubMed ID: 26433170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
    Wong AK; Chan RC; Nichols WS; Bose S
    Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of the effectiveness of BMRT-HPV for cervical cancer screening].
    Duan LF; Du H; Wang C; Huang X; Qu XF; Duan XZ; Liu Y; Shi B; Zhang W; Wei LH; Belinson L; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Oct; 55(10):708-715. PubMed ID: 33120484
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.